Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19
Author(s): Andrea Di Lenarda , Nicola Ferri , Massimiliano Lanzafame , et al Added: 9 months ago

COVID-19

CV Disease in Special Populations
Cardiovascular Effects of NSAIDs: A Review With a Focus on RA Patients
Author(s): Eirik Ikdahl , Anne Kerola , Eli Sollerud , et al Added: 4 months ago

Prevention & Chronic Conditions
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 9 months ago

Anticoagulation
SUCCESS PTA: 12-Month Data from SELUTION SLR™ DEB
Author(s): Michael Lichtenberg Added: 2 weeks ago
12 Month Outcomes of the SUCCESS PTA Study show consistent safety and effectiveness in claudicant and CLTI patients when using the SELUTION SLR™ drug eluting balloon.Dr Michael Lichtenberg (Vascular Centre Clinic Arnsberg, Arnsberg, DE) joins us to discuss the SUCCESS PTA study, a prospective, observational global registry evaluating the SELUTION SLR DEB in 723 patients across Europe, Asia and… View more

Intervention

Vascular Disease and Surgery
ESC HF 25: CRISPR in ATTR-CM: Hereditary vs Wild-Type
Author(s): Marianna Fontana Added: 3 days ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,… View more

Heart Failure
View from the Thoraxcenter: EuroPCR 25 Late-breaking Preview
Author(s): Joost Daemen , Nicolas M Van Mieghem Added: 1 week ago
Step into the forefront of interventional cardiology with distinguished experts Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) as they provide a comprehensive overview of EuroPCR 2025's most anticipated late-breaking trials.Optimize your conference preparation through this essential preview, where expert commentary outlines the clinical significance of this… View more

Intervention
Research Area(s) / Expertise:
ACC 25: The SMART-CHOICE 3 Trial
Author(s): Joo-Yong Hahn Added: 1 month ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel… View more

Anticoagulation

Intervention
HFA 24 Late-Breaker Discussion: The TITRATE-HF Study
Author(s): Jasper J Brugts , Harriette Van Spall Added: 1 year ago
HFA 24 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) joined onsite by Dr Jasper Brugts (Erasmus University Medical Centre, NL) to discuss the first results from the TITRATE-HF study.TITRATE-HF is a real-world multicenter longitudinal study which aims to assess drug sequencing strategies for guideline-directed medical therapy (GDMT) initiation in patients with de novo,… View more

Heart Failure
EuroPCR 24: The CAGEFREE II Trial
Author(s): Ling Tao Added: 12 months ago
EuroPCR 2024 — Investigator, Dr Ling Tao joins us to discuss the findings from the CAGEFREE II trial.Compared to drug-eluting stents, drug-coated balloons are associated with faster vessel healing and reduced thrombotic burden, therefore patients treated with DCBs require a less intensive antiplatelet therapy. CAGEFREE II investigated the effectiveness and safety of a tailored one-month DAPT… View more

Intervention